首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1347975

全球风疹诊断测试市场 - 2023-2030

Global Rubella Diagnostic Testing Market - 2023-2030

出版日期: 2023年09月11日 | 出版商:

DataM Intelligence | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

麻疹具有高度传染性。大约十分之九未受到保护的人会在接触麻疹病毒后被感染。怀孕早期感染风疹的孕妇生出患有先天性风疹综合征（CRS）的婴儿的可能性高达 90%。一名麻疹患者可感染 12 至 18 人，使其成为传染性最强但可通过疫苗预防的疾病。

接触麻疹的易感人群（未接种疫苗/从未患过麻疹）中约有十分之九会患病。 33% 患有先天性风疹综合征的婴儿在一岁之前死亡。风疹 IgG 血清学检测应用于评估风疹免疫力，包括怀疑先天性风疹综合征的怀孕前、怀孕期间和怀孕后。怀孕期间感染风疹可导致流产（受孕 20 週内胎儿流产）和死产（20 週后死亡）。

市场动态

世界某些地区麻疹疫情增加

世界某些地区再次爆发麻疹疫情增加了诊断检测。美国疾病控制与预防中心的数据显示，儘管美国在2000年就宣布麻疹被消灭，但2019年美国31个州报告了近1300例麻疹病例，是1992年以来的最高数字。世界卫生组织于2023 年8 月上旬表示，与世界其他国家相比，印度的麻疹病例数最多，截至2023 年有57,550 例。也门有24,596 例，巴基斯坦有10,549 例。

2000 年至 2021 年间，麻疹疫苗在全球挽救了超过 5600 万人的生命。然而，由于其再次发生，这一数字正在下降。诊断测试可用于治疗生活在观察到麻疹疫情的特定地区的个人的疾病。据联合国国际儿童紧急基金会（UNICEF）称，全球疫苗接种覆盖率已于2022年恢復。然而，全球仍有2050万儿童错过了救生疫苗，比2019年增加了210万。

2022 年，儘管印度的覆盖率达到 93%，但仍有 160 万儿童未接种疫苗和疫苗接种不足。数量的减少使得该疾病在少数地区再次出现，并立即传播到其他地区，因为该疾病具有高度传染性。疫情发生在疫苗接种率最低的地区。因此，预计上述因素将在预测期内推动市场。

推动市场的其他一些因素包括测试程序的进步、风疹疫情的再次爆发以及疫苗接种数量的减少，这些因素预计将在未来一段时间内推动市场。

孕妇检测结果呈假阳性

风疹 IgM 检测应仅限于疑似风疹病例。不建议用于筛查无症状人群。类风湿因子的存在也可能导致 IgM 假阳性。由于存在假阳性结果的可能性，IgM 不应包含在常规检测中以确定先前风疹免疫的证据。对无症状、未暴露的孕妇进行风疹 IgM 检测是不合适的，因为可能会出现假阳性结果，从而产生误导。

Overview

Measles is highly contagious. Around 9 out of 10 people who are not protected will become infected following exposure to the measles virus. A pregnant woman infected with rubella in early pregnancy has up to a 90% chance of giving birth to a baby with congenital rubella syndrome (CRS). One person with measles can infect 12-18 people, making it the most infectious yet vaccine-preventable disease.

Around 9 out of 10 susceptible people (unvaccinated/have never had measles) who are exposed to measles will get sick. 33% of infants with congenital rubella syndrome die before one year. Rubella IgG serology testing should be used for assessing rubella immunity, including before, during, and after pregnancy suspecting congenital rubella syndrome. Rubella infection during pregnancy can lead to miscarriage (loss of the fetus within 20 weeks of conception) and stillbirth (death after 20 weeks).

Market Dynamics

Increasing measles outbreaks in certain parts of the world

The Reoccurrence of measles outbreaks in some parts of the world increases diagnostic testing. According to the Centers for Disease Control and Prevention, although measles was declared eliminated in the United States in 2000, almost 1,300 cases of measles were reported in 31 states in the U.S. in 2019, the most significant number since 1992. According to data, the World Health Organization said in early August 2023, India had the highest number of measles cases compared to the rest of the world, with 57,550 cases as of 2023. Yemen with 24,596 and Pakistan with 10,549 patients.

Measles vaccines saved more than 56 million lives worldwide between 2000-2021. However, the numbers are declining due to its reoccurrence. Diagnostic testing comes into play to treat the disease in individuals living in specific regions where measles outbreaks are observed. According to the United Nations International Children's Emergency Fund (UNICEF), global vaccination coverage has recovered in 2022. However, there are still 20.5 million children missing out on lifesaving vaccines globally, 2.1 million more than in 2019.

In 2022, India accounted for 1.6 million unvaccinated and under-vaccinated children despite achieving 93 percent coverage. These reducing numbers make the reoccurrence of the disease in a few regions and immediately spread to other regions as well because the disease is highly contagious. The outbreaks happen in those areas where the vaccination is at its lowest. Hence, the above factor is expected to drive the market in the forecast period.

Some of the other factors that drive the market are advancements in testing procedures, reoccurrence of rubella outbreaks, and decreased number of vaccinations are a few factors that are expected to drive the market in the forthcoming period.

False positive test results in pregnant women

Rubella IgM testing should be limited to suspected rubella cases. It is not recommended for screening asymptomatic people. The presence of rheumatoid factor can also result in a false positive IgM. Due to the possibility of false positive results, IgM should not be included in routine testing to determine evidence of prior rubella immunity. Rubella IgM testing in asymptomatic, unexposed pregnant people is inappropriate because false positive results can occur, which can be misleading.

Segment Analysis

The global rubella diagnostic testing is segmented based on diagnostic test, age group, end user, and region.

The enzyme immunoassay (EIA) is expected to hold the largest market share during the forecast period, owing to the rising incidences of rubella and the advantages of the enzyme immunoassay (EIA) method. For instance, the enzyme immunoassay is the most used as it is relatively inexpensive, technically easy to perform, rapid, and susceptible.

EIA is used to detect rubella-specific immunoglobulin G (IgG) antibodies. IgM testing is the most commonly performed technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies the immune system makes to kill the rubella virus, which remains in the bloodstream for years. The EIA is also suitable for diagnosing acute infections, as a significant increase in antibody levels was detected in all paired specimens tested from patients with acute rubella infection.

In July 2021, it reported that measles and rubella are two of the most globally critical vaccine-preventable diseases (VPD), and measuring antibodies to measles and rubella viruses in samples collected from serosurveys can play an important role in estimating population immunity and guiding immunization activities and enzyme immunoassay is the most convenient method and accessible approach for detecting the rubella virus. Hence, the efficacy is elevated if ELISA kits are used. This factor is expected to drive the market in the forecast period.

Geographical Analysis

Asia Pacific is expected to hold the largest segment in the market. According to information from the Centers for Disease Control and Prevention, India has the highest number of cases between April and September 2022. Pakistan stayed in 7th position with 3635 cases, while the US had 33 cases by the end of 2022.

Due to the increased number of cases in 2022, the Indian government has launched a scheme to improve the diagnostic services related to measles disease. For instance, in July 2022, the Pradhan Mantri Surakshit Matritva Abhiyan by the Ministry of Health & Family Welfare (MoHFW), Government of India, to improve the quality and coverage of antenatal care (ANC), including diagnostics and counseling services, as part of the Reproductive Maternal Neonatal Child and Adolescent Health (RMNCH + A) strategy.

COVID-19 Impact Analysis on Rubella Diagnostic Testing Market

COVID-19 negatively impacted the global market during the outburst because to prevent further COVID-19 infection, restrictions and regulations were imposed, making it difficult for people to perform rubella diagnoses affecting the sales of the rubella diagnostic kits. Furthermore, during the pandemic, regular vaccination programs were on hold, which according to NIH estimation, put 80 million infants at risk of infection by measles, polio, and diphtheria, negatively impacting the global market.

Market Segmentation

By Diagnostic Technique

Latex Agglutination
Liver Function Tests
Enzyme Immunoassay (EIA)
Radioimmunoassay (RIA)
Fluorescent Immunoassay (FIA)
Others

By Age Group

Neonates
Teenagers
Adults

By End User

Hospitals and Clinics
Cancer Diagnostic Centers
Ambulatory Surgical Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the rubella diagnostic testing market include: Siemens Healthineers AG, Bio Rad Laboratories Inc., Abbott Laboratories, BioMerieux SA, Thermo Fisher Scientific Inc., ZEUS, Scientific Inc., F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, InDevR, Inc., and Beckman Coulter Inc. among others.

Key Developments

In 2023, The Immunization Agenda 2030 Measles & Rubella Partnership (M&RP), a partnership led by the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccines Alliance, the Bill and Melinda French Gates Foundation, UNICEF and WHO, to achieve the IA2030 measles and rubella specific targets.
In August 2022, Roche reported that the United States Food and Drug Administration (USFDA) has approved a label expansion for its Ventana MMR RxDx Panel that provides clinicians with access to a fully automated panel of mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).
In 2021, The United Kingdom Health Security Agency's Immunization and Vaccine-Preventable Diseases Division launched a new rash-fever surveillance scheme. The aim is to increase the number of samples tested for measles and rubella diagnostic testing. The program was initiated by the United Kingdom government, which distributed rubella diagnostic kits for rapid rubella testing.

Why Purchase the Report?

To visualize the global rubella diagnostic testing segmentation based on diagnostic test, age group, end user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of rubella diagnostic testing market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global rubella diagnostic testing market report would provide approximately 61 tables, 61 figures, and 185 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Diagnostic test
3.2. Snippet by Age Group
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Measles Outbreaks in Certain Parts of the World
- 4.1.2. Restraints
  - 4.1.2.1. False Positive Test Results in Pregnant Women
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Diagnostic test

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test
- 7.1.2. Market Attractiveness Index, By Diagnostic Test
7.2. Latex Agglutination*
- 7.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test
- 7.2.2. Market Attractiveness Index, By Diagnostic Test
7.3. Liver Function Tests
7.4. Enzyme Immunoassay (EIA)
7.5. Radioimmunoassay (RIA)
7.6. Fluorescent Immunoassay (FIA)
7.7. Others

8. By Age Group

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 8.1.2. Market Attractiveness Index, By Age Group
8.2. Neonates*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Teenagers
8.4. Adults

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals and Clinics*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic laboratories
9.4. Ambulatory surgical Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic test
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Siemens Healthineers AG
- 12.1.1. Company Overview
- 12.1.2. Diagnostic technique Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Bio Rad Laboratories Inc.
12.3. Abbott Laboratories
12.4. BioMerieux SA
12.5. Thermo Fisher Scientific Inc.
12.6. ZEUS Scientific Inc.
12.7. F. Hoffmann-La Roche Ltd
12.8. Ortho Clinical Diagnostics
12.9. InDevR, Inc.
12.10. Beckman Coulter Inc.

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Services
13.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格